Necrosis News and Research

RSS

Reversing inflammation in fluid near brain's cortex may provide solution to Parkinson's disease

Reversing inflammation in the fluid surrounding the brain's cortex may provide a solution to the complex riddle of Parkinson's, according to researchers who have found a link between pro-inflammatory biomarkers and the severity of symptoms such as fatigue, depression and anxiety in patients with the chronic disease.

29 Aug 2013

Inflammatory status upregulated in first-episode schizophrenia

Patients with first-episode schizophrenia exhibit upregulation of key proinflammatory molecules, study findings show.

28 Aug 2013

Takeda announces publication of data from two vedolizumab Phase 3 studies for ulcerative colitis and Crohn’s disease

Takeda Pharmaceutical Company Limited today announced that results from two Phase 3 studies evaluating vedolizumab, an investigational humanized monoclonal antibody, for the treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease, were published in the August 22, 2013 issue of the New England Journal of Medicine.

22 Aug 2013

New antibody drug shows positive results for treating Crohn's disease, ulcerative colitis

Vedolizumab, a new intravenous antibody medication, has shown positive results for treating both Crohn's disease and ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The findings, published in two papers, will appear in the August 22 issue of the New England Journal of Medicine (NEJM).

22 Aug 2013

New studies in mice support toxic role of aluminum in neurodegenerative conditions

Investigators have linked aluminum accumulation in the brain as a possible contributing factor to neurodegenerative disorders such as Alzheimer's disease. A new study published in Restorative Neurology and Neuroscience sheds light on the mechanism underlying aluminum-induced neuronal cell death and identifies necrostatin-1 as a substance which counteracts several of aluminum's neurotoxic effects.

6 Aug 2013

Necrostatin-1: A substance which counteracts several of aluminum's neurotoxic effects

New Studies in Mice Support Toxic Role of Aluminum in Neurodegenerative Conditions, According to Report in Restorative Neurology and Neuroscience

3 Aug 2013

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration approval of SIMPONI ARIATM (golimumab) for infusion for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate.

19 Jul 2013

Inovio's electroporation technology enhances ability of DNA therapy to stimulate blood vessel growth

Inovio Pharmaceuticals, Inc. announced today that the use of its proprietary electroporation technology significantly enhanced the ability of a DNA therapy to stimulate blood vessel growth, which may be beneficial for the treatment of critical limb ischemia and other forms of peripheral arterial disease.

18 Jul 2013

Weekend reading: Doctors who decide, death desires, and decisions

On the last week of April earlier this year, a small committee of doctors met quietly in a midsized ballroom at the Renaissance Hotel in Chicago. There was an anesthesiologist, an ophthalmologist, a radiologist, and so on-;thirty-one in all, each representing their own medical specialty society, each a heavy hitter in his or her own field.

12 Jul 2013

University of Pennsylvania resident receives inaugural Dr. Mark G. Lebwohl Medical Dermatology Fellowship

The National Psoriasis Foundation awarded Zelma Chiesa Fuxench, M.D., of the University of Pennsylvania, its inaugural Dr. Mark G. Lebwohl Medical Dermatology Fellowship, recognizing her work as a promising psoriasis and psoriatic arthritis researcher.

9 Jul 2013

Idera Pharmaceuticals reports Phase 1 clinical trial results of IMO-8400

Idera Pharmaceuticals, Inc. announced results of a Phase 1 clinical trial of IMO-8400, a first-in-class antagonist of Toll-like Receptors 7, 8, and 9 being developed for potential applications in autoimmune and inflammatory diseases.

2 Jul 2013

Hospira receives positive opinion from EMA's CHMP for EC approval of Inflectra

Hospira, the world's leading provider of injectable drugs and infusion technologies, today received a positive opinion from the European Medicines Agency Committee for Medicinal Products for Human Use, recommending the European Commission approval of Inflectra (infliximab) for rheumatoid arthritis, inflammatory bowel disease and plaque psoriasis.

28 Jun 2013

Report alerts clinicians, public about catastrophic dangers of contaminated epidural injections

Investigators from the Centers for Disease Control and Prevention describe pathologic findings from 40 case reports of fungal infection in patients who had been given contaminated epidural, paraspinal, or intra-articular (into joints) steroid injections and correlate these findings with clinical and laboratory data.

26 Jun 2013

Endosonographic aspiration procedures result in greater diagnostic yield in treating pulmonary sarcoidosis

Among patients with suspected stage I/II pulmonary sarcoidosis who were undergoing confirmation of the condition via tissue sampling, the use of the procedure known as endosonographic nodal aspiration compared with bronchoscopic biopsy, the current diagnostic standard, resulted in greater diagnostic yield, according to a study in the June 19 issue of JAMA.

19 Jun 2013

Smoking before surgery can lead to morbidity and complications for neurosurgical procedures

The effects of long-term cigarette smoking on morbidity and mortality have long been known. In a more immediate sense, smoking in the days and weeks before surgery can lead to morbidity and complications for many surgical procedures.

19 Jun 2013

Study shows patients with avascular necrosis have turned to stem cell therapy for aid

Stem cells have long been touted as the next big thing. Well just maybe, it is here. According to Dr. Dennis Lox, some patients with a disorder of the bone called avascular necrosis (AVN), have turned to stem cell therapy for aid.

15 Jun 2013

One-third of RA patients discontinue therapy within the first year of treatment

Data presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, show that up to one-third of rheumatoid arthritis patients discontinue or change therapy within the first year of treatment.

13 Jun 2013

Celgene announces positive results from first phase III study of apremilast in psoriatic arthritis

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced 52-week results from PALACE 1, the Company's first phase III study in psoriatic arthritis at the European Congress of Rheumatology annual meeting in Madrid, Spain.

12 Jun 2013

Six top scientists studying psoriasis receive NPF research grants to discover new treatments for chronic diseases

Six of the top scientists studying psoriasis-the most common autoimmune disease in the country, affecting 7.5 million Americans-and psoriatic arthritis, an inflammatory joint and tendon disease affecting up to 30 percent of people with psoriasis, received National Psoriasis Foundation (NPF) research grants totaling $450,000 for projects that aim to discover new treatments and a cure for these chronic diseases.

5 Jun 2013

Only one-fifth of RA patients had overall adherence rate to prescribed oral medications, study finds

A new study conducted in an ethnically diverse and predominantly low income population found that only one-fifth of rheumatoid arthritis patients had an overall adherence rate to prescribed oral medications at 80% or greater.

1 Jun 2013